DanCann Pharma A/S in advanced talks with new investor of additional DKK 12 million for topping up the outcome of the TO 2’s
COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby inform the market and its investors that it is currently engaged in advanced discussions with a new investor regarding an additional DKK 12 million to supplement the outcome of TO 2's. The agreement is based on a loan agreement with conversion options and initially has a scope of DKK 12 million, which can potentially increase to a total of DKK 18 million. The agreement will be subject to an approval on an Extra General Meeting.